Phase 2 Completed N=154 Randomized Double-blind Treatment

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Glaucoma Open-angle

Source: ClinicalTrials.gov NCT02754596 ↗

Enrolled (actual)

154

Serious AEs

10.4%

Results posted

Aug 2023

Primary outcomePrimary: IOP (mmHg) Change From Baseline at Week 12 — -8.3; -7.7; -7.5 mmHg

Summary

This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.

Outcome Measures

Outcome	Result	p-value
PRIMARY IOP (mmHg) Change From Baseline at Week 12	-8.3; -7.7; -7.5	—

Eligibility Criteria

Inclusion Criteria

Open angle glaucoma

Exclusion Criteria

Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders.
Functionally significant visual field loss, including severe nerve fiber bundle defects.
Prior glaucoma surgery.
Uncontrolled systemic disease, pregnant females or those planning a pregnancy.
Other ocular status conditions, etc.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02754596). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.